Bookmark and Share

News & Events

Alan R. Shuldiner, MD, to Become Associate Dean and Director of New Program in Personalized Medicine

Tuesday, March 08, 2011

Shuldiner_Alan_2.jpg
 Congratulations to Dr. Shuldiner on his new appointment!
 

Alan R. Shuldiner, MD, the John L. Whitehurst Professor of Medicine, has been appointed Associate Dean and Director of the Program in Personalized Medicine (PPM).

The School of Medicine and the University of Maryland Medical Center have jointly committed to the creation of a top-tier Program in Personalized Medicine. Dr. Shuldiner will be charged to develop, build and lead this program to a level of national and international recognition, with innovative educational, research and clinical programs. This new program will be integrated with the existing Program in Genetics and Genomic Medicine, which Dr. Shuldiner currently leads.  

Dr. Shuldiner received his MD degree from Harvard Medical School in 1984. He was a resident in internal medicine at Columbia University Medical Center in New York City and a Medical and Senior Fellow in Endocrinology and Metabolism in the Diabetes Branch at the NIH. In 1991, he joined the faculty of Johns Hopkins University. In 1997, Dr. Shuldiner was recruited to the University of Maryland School of Medicine as Professor and Head of the Division of Diabetes, Obesity and Nutrition in the Department of Medicine, which became the Division of Endocrinology, Diabetes and Nutrition in 1999. In 2005, he was invested as the John Whitehurst Professor of Medicine and was appointed the Director of the University of Maryland School of Medicine Interdepartmental Program in Genetics and Genomic Medicine. Dr. Shuldiner is also a Core Investigator at the Geriatric Research and Education Clinical Center (GRECC) at the Baltimore Veterans Administration Medical Center, and Network Director of the Joslin Diabetes Center at the Medical Center. He is also the Director of the Mid-Atlantic Nutrition Obesity Research Center (NORC).

Dr. Shuldiner’s major research interests are in the molecular basis and genetics of type-2 diabetes, obesity and insulin resistance. He has published over 200 peer-reviewed articles, and he has a citation index of 7,759 and an H-index of 46. Dr. Shuldiner has over $38 million in total current extramural funding for his research, including support from the NIH, American Diabetes Association and Juvenile Diabetes Foundation.

"I know that Dr. Shuldiner will do an outstanding job in assuming this additional leadership responsibility," says E. Albert Reece, MD, PhD, MBA, Vice President for Medical Affairs, University of Maryland, and the John Z. and Akiko K. Bowers Distinguished Professor and Dean, University of Maryland School of Medicine. "I am confident that with his talent, leadership and energy, Dr. Shuldiner will lead our new University of Maryland Program in Personalized Medicine to a position of tremendous presence and national prominence. Please join me in congratulating Dr. Shuldiner in his new appointment, and for his continuing leadership contributions to the School of Medicine, the Medical Center, and the overall university campus community."

Dr. Shuldiner's new appointment will be effective April 1, 2011.

Contact

Caelie Haines
Manager, Public Affairs
(410) 706-7508
chaines@som.umaryland.edu

Search Articles

Learn More